Ligand's Captisol formulation technology has helped it form partnerships with several leading healthcare companies that provide it with funds as milestone and royalty payments. Royalties depend on the sales of its two key partnered assets, Novartis AG's ( NVS - Free Report ) Kyprolis and Amgen's Promacta.